Puma Biotechnology (PBYI) Capital Expenditures (2011 - 2025)
Puma Biotechnology (PBYI) posted Capital Expenditures of -$36000.0 for Q4 2025, down 137.11% on a QoQ basis from $97000.0 in Q3 2025, and down 200.0% year-over-year from $36000.0 in Q4 2024.
Puma Biotechnology (PBYI) Capital Expenditures (2011 - 2025) Analysis & Trends
Puma Biotechnology's Capital Expenditures history runs 12 years deep, the most recent figure standing at -$36000.0 for Q4 2025.
- Quarterly Capital Expenditures fell 200.0% year-over-year to -$36000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $10000.0 (down 91.45% YoY) and the FY2025 annual result came in at $71000.0, up 26.79% from the prior year.
- Capital Expenditures was -$36000.0 for Q4 2025 at Puma Biotechnology, down from $97000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $97000.0 in Q3 2025 and bottomed at -$51000.0 in Q2 2025.
- A 3-year average of $15333.3 and a median of $10000.0 in 2024 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 870.0% in 2025, while the deepest fall reached 610.0% in 2025.
- Puma Biotechnology's Capital Expenditures stood at $26000.0 in 2023, then jumped by 38.46% to $36000.0 in 2024, then plunged by 200.0% to -$36000.0 in 2025.
- Business Quant data shows PBYI's Capital Expenditures at -$36000.0 in Q4 2025, $97000.0 in Q3 2025, and -$51000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Puma Biotechnology | 407.27 Mn | 368.99 Mn | 34.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -36,000.00 |
| Dec 31, 2025 | -36,000.00 |
| Sep 30, 2025 | 97,000.00 |
| Sep 30, 2025 | 97,000.00 |
| Jun 30, 2025 | -51,000.00 |
| Jun 30, 2025 | -51,000.00 |
| Mar 31, 2025 | 61,000.00 |
| Mar 31, 2025 | 61,000.00 |
| Dec 31, 2024 | 36,000.00 |
| Dec 31, 2024 | 36,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Dec 31, 2023 | 26,000.00 |
| Dec 31, 2023 | 26,000.00 |
| Sep 30, 2023 | -15,000.00 |
| Sep 30, 2023 | -15,000.00 |
| Dec 31, 2020 | 23,000.00 |
| Dec 31, 2020 | 23,000.00 |